Testosterone replacement in prostate cancer survivors with hypogonadal symptoms

BJU International - Tập 105 Số 10 - Trang 1397-1401 - 2010
Robert L. Leibowitz1, Tanya B. Dorff1, Steven Tucker2, James T. Symanowski3, Nicholas J. Vogelzang4
1Compassionate Oncology Medical Group, University of Southern California, Los Angeles CA, USA,
2Pacific Cancer Centre, Singapore
3Nevada Cancer Institute, Las Vegas, NV and
4US Oncology, Comprehensive Cancer Centers of Nevada, USA

Tóm tắt

Study Type – Therapy (case series)
Level of Evidence 4OBJECTIVETo describe the clinical outcomes of prostate cancer survivors who were treated with high‐dose testosterone‐replacement therapy (TRT) for the relief of hypogonadal symptoms.PATIENTS AND METHODSWe reviewed the records of 96 patients who received TRT after initial management for prostate cancer from 2000 to 2007.RESULTSIn all, 41 men had prostate‐specific antigen (PSA) progression (PSA Working Group) while on TRT, but only seven had radiographic progression of disease. Fifty‐six men discontinued TRT due to increasing PSA levels, and 59% of these men had significant reductions in PSA level with no additional intervention. In all, 31 men remain on TRT with no PSA or radiological progression at a median of 36.7 months; nine men stopped TRT for reasons other than progression. Characteristics associated with continuing TRT were radical prostatectomy as primary management, a low PSA level when starting TRT, and concurrent use of dutasteride. Hypogonadal symptoms were alleviated in most cases.CONCLUSIONSWhile most men in this series had increasing PSA levels during TRT, stopping TRT typically resulted in PSA declines. A subset of men were able to remain on TRT for several years without disease progression.

Từ khóa


Tài liệu tham khảo

10.3322/canjclin.57.1.43

10.1046/j.1464-410X.2002.2822.x

10.1210/jcem.86.2.7219

10.1016/S0960-0760(03)00203-6

10.1210/jc.2004-1933

10.1001/archsurg.1941.01210140043004

10.1056/NEJMra022251

10.1097/01.ju.0000091104.71869.8e

10.1038/sj.pcan.4500833

10.1002/cncr.22438

10.1111/j.1464-410X.2008.07882.x

10.1210/jc.85.8.2839

10.1210/jc.84.8.2647

10.1210/jc.84.6.1966

10.1093/gerona/57.5.M321

10.1016/j.ejca.2006.01.029

10.1016/S0090-4295(99)80092-2

10.1016/S0090-4295(96)00381-0

10.1200/JCO.1999.17.11.3461

10.1002/1097-0142(19820401)49:7<1373::AID-CNCR2820490712>3.0.CO;2-G

10.1073/pnas.93.21.11802

10.1016/S0090-4295(99)80021-1

10.1056/NEJMoa030660

10.1158/1078-0432.CCR-06-0184

10.1097/01.ju.0000136430.37245.b9

MostaghelEA ColemanIM ColemanRet al.Prostate gene expression changes after neoadjuvant 5α‐reductase inhibition: identification of potential chemopreventive mechanisms.ASCO Prostate Cancer Symp2007; Abstract ♯1

10.1016/j.eururo.2007.10.052

Thông tin
Thông tin xuất bản

BJU International

Tập 105 Số 10

1397-1401

Thông tin tác giả